Medically reviewed on Sep 10, 2018
(soo ma TRIP tan)
- Sumatriptan Succinate
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Exhaler Powder, Nasal, as succinate [strength expressed as base]:
Onzetra Xsail: 11 mg per nosepiece (2 ea)
Imitrex: 5 mg/actuation (1 ea); 20 mg/actuation (1 ea)
Generic: 5 mg/actuation (1 ea); 20 mg/actuation (1 ea)
Solution, Subcutaneous, as succinate [strength expressed as base]:
Imitrex: 6 mg/0.5 mL (0.5 mL)
Generic: 6 mg/0.5 mL (0.5 mL)
Solution, Subcutaneous, as succinate [strength expressed as base, preservative free]:
Generic: 6 mg/0.5 mL (0.5 mL [DSC])
Solution Auto-injector, Subcutaneous, as succinate [strength expressed as base]:
Alsuma: 6 mg/0.5 mL (0.5 mL [DSC])
Imitrex STATdose System: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)
Zembrace SymTouch: 3 mg/0.5 mL (0.5 mL)
Generic: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)
Solution Cartridge, Subcutaneous, as succinate [strength expressed as base]:
Imitrex STATdose Refill: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)
Generic: 4 mg/0.5 mL (0.5 mL)
Solution Jet-injector, Subcutaneous, as succinate [strength expressed as base]:
Sumavel DosePro: 4 mg/0.5 mL (0.5 mL [DSC]); 6 mg/0.5 mL (0.5 mL)
Solution Prefilled Syringe, Subcutaneous, as succinate [strength expressed as base, preservative free]:
Generic: 6 mg/0.5 mL (0.5 mL [DSC])
Tablet, Oral, as succinate [strength expressed as base]:
Imitrex: 25 mg, 50 mg, 100 mg
Generic: 25 mg, 50 mg, 100 mg
Brand Names: U.S.
- Alsuma [DSC]
- Imitrex STATdose Refill
- Imitrex STATdose System
- Onzetra Xsail
- Sumavel DosePro
- Zembrace SymTouch
- Antimigraine Agent
- Serotonin 5-HT1B, 1D Receptor Agonist
Selective agonist for serotonin (5-HT1B and 5-HT1D receptors) on intracranial blood vessels and sensory nerves of the trigeminal system; causes vasoconstriction and reduces neurogenic inflammation associated with antidromic neuronal transmission correlating with relief of migraine
Vd (central): SubQ: 50 L; Vd (apparent): Oral, Intranasal powder and solution: 2.7 L/kg
Hepatic to an indole acetic acid metabolite (inactive) which then undergoes ester glucuronide conjugation; may be metabolized by monoamine oxidase (MAO); extensive first-pass metabolism following oral administration
Intranasal: Urine (42% of total dose as indole acetic acid metabolite; 3% of total dose as unchanged drug)
Oral: Urine (~60% of total dose, mostly as indole acetic acid metabolite; 3% of total dose as unchanged drug); feces (~40%)
SubQ: Urine (38% of total dose as indole acetic acid metabolite; 22% of total dose as unchanged drug)
Onset of Action
Oral: ~30 minutes; Intranasal: Solution: ~15 to 30 minutes; SubQ: ~10 minutes; Peak effect: Oral: 2 to 4 hours
Time to Peak
Oral: 2 to 2.5 hours; Intranasal: Powder: ~45 minutes; SubQ: 12 minutes (range: 4 to 20 minutes)
Distribution: 15 minutes; Terminal: 2 hours; range: 1 to 4 hours
14% to 21%
Special Populations: Hepatic Function Impairment
Bioavailability following oral administration may be markedly increased in patients with hepatic disease.
Use: Labeled Indications
Migraine: Intranasal, Oral, SubQ: Acute treatment of migraine with or without aura in adults
Cluster headache: SubQ (excluding Zembrace): Acute treatment of cluster headache episodes in adults
Off Label Uses
Migraine (children/adolescents) (Intranasal)
Sumatriptan nasal spray has been studied for the treatment of migraine headaches in pediatric patients in several controlled trials. The published data show consistently favorable results. The current practice guidelines state that sumatriptan nasal spray should be considered an effective treatment option in pediatric patients.
Migraine (children/adolescents) (Oral)
All 3 dosage forms of sumatriptan have been studied for the treatment of migraine headaches in pediatric patients. The data for sumatriptan nasal spray are consistently positive. However, the published data for the oral dosage form are limited to a single controlled trial of fewer than 25 patients. American Academy of Neurology guidelines consider there to be insufficient evidence to make a recommendation for the use of any oral triptans in children or adolescents.
Migraine (children/adolescents) (SubQ)
All 3 dosage forms of sumatriptan have been studied for the treatment of migraine headaches in pediatric patients. The data for intranasal sumatriptan are consistently positive. However, the published data for the subcutaneous dosage form are limited by the small sample size and study design. American Academy of Neurology guidelines consider there to be insufficient evidence to make a recommendation for the use of any oral triptans in children or adolescents and further state that there are insufficient data to make an assessment of subcutaneous sumatriptan.
Hypersensitivity (eg, angioedema, anaphylaxis) to sumatriptan or any component of the formulation; ischemic heart disease or signs or symptoms of ischemic heart disease (coronary artery vasospasm, Prinzmetal angina, angina pectoris, myocardial infarction, silent myocardial ischemia); history of cerebrovascular syndromes (including strokes, transient ischemic attacks), history of hemiplegic or basilar migraine; peripheral vascular disease (including ischemic bowel disease); uncontrolled hypertension; use within 24 hours of ergotamine derivatives; use within 24 hours of another 5-HT1 agonist; concurrent administration or within 2 weeks of discontinuing an MAO type A inhibitors; Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; severe hepatic impairment (excluding Sumavel)
Canadian labeling: Additional contraindications (not in the US labeling): Valvular heart disease; significant underlying cardiovascular disease (eg, atherosclerotic disease, congenital heart disease); ophthalmoplegic migraine
Oral: A single dose of 25 mg, 50 mg, or 100 mg (taken with fluids). If a satisfactory response has not been obtained at 2 hours, a second dose may be administered. Results from clinical trials show that initial doses of 50 mg and 100 mg are more effective than doses of 25 mg, and that 100 mg doses do not provide a greater effect than 50 mg and may have increased incidence of side effects. Although doses of up to 300 mg/day have been studied, the total daily dose should not exceed 200 mg. The safety of treating an average of >4 headaches in a 30-day period have not been established.
Powder: A single dose of 22 mg (11 mg nosepiece in each nostril). If headache has not resolved within 2 hours or returns, the dose may be repeated once ≥2 hours after the first dose (maximum: 44 mg [4 nosepieces] per 24 hours or 22 mg [2 nosepieces] and one dose of another sumatriptan product [separated by ≥2 hours] per 24 hours). The safety of treating an average of >4 headaches in a 30-day period has not been established.
Solution: A single dose of 5 mg, 10 mg, or 20 mg administered in one nostril. A 10 mg dose may be achieved by administering a single 5 mg dose in each nostril. If headache has not resolved within 2 hours or returns, the dose may be repeated once after 2 hours, not to exceed a total daily dose of 40 mg. In clinical trials, a greater number of patients responded to initial doses of 20 mg versus 5 or 10 mg. The safety of treating an average of >4 headaches in a 30-day period has not been established.
Alsuma: 6 mg; Imitrex: 6 mg, if side effects are dose limiting, use lower doses 1 to 5 mg; Sumavel: 6 mg, if side effects are dose limiting, use 4 mg. May repeat if needed ≥1 hour after initial dose (maximum: 6 mg per dose; two 6 mg injections per 24-hour period; or maximum cumulative dose of 12 mg in 24 hours, separated by at least 1 hour). However, controlled clinical trials have failed to document a benefit with administration of a second 6 mg dose in nonresponders.
Zembrace: 3 mg; may repeat if needed (up to 4 injections) with each injection separated by at least 1 hour (may also give following the dose of another sumatriptan product if separated by at least 1 hour); do not exceed 12 mg in 24 hours.
Cluster headache: SubQ (excluding Zembrace): Initial: 6 mg; may repeat if needed ≥1 hour after initial dose (maximum: 6 mg per dose; two 6 mg injections per 24-hour period). However, controlled clinical trials have failed to document a benefit with administration of a second 6 mg dose in nonresponders.
Refer to adult dosing.
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). However, dosage adjustment not expected due to extensive metabolism to inactive agents.
Dosing: Hepatic Impairment
Mild to moderate hepatic impairment:
Oral: Bioavailability of oral sumatriptan is increased with liver disease. If treatment is needed, do not exceed single doses of 50 mg.
Intranasal: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). However, because the solution and powder do not undergo first-pass metabolism, levels would not be expected to be altered.
Subcutaneous: No dosage adjustment necessary.
Severe hepatic impairment: Oral, intranasal, and subcutaneous (Alsuma, Imitrex, and Zembrace injection) formulations are contraindicated in severe hepatic impairment. Sumavel is not recommended in severe hepatic impairment.
A 5 mg/mL oral liquid preparation made from tablets and one of three different vehicles (Ora-Sweet®, Ora-Sweet® SF, or Syrpalta® syrups). Note: Ora-Plus® Suspending Vehicle is used with Ora-Sweet® or Ora-Sweet® SF to facilitate dispersion of the tablets (Ora-Plus® is not necessary if Syrpalta® is the vehicle). Crush nine 100 mg tablets in a mortar and reduce to a fine powder. Add 40 mL of Ora-Plus® in 5 mL increments and mix thoroughly between each addition; rinse mortar and pestle 5 times with 10 mL of Ora-Plus®, pouring into bottle each time, and add quantity of appropriate syrup (Ora-Sweet® or Ora-Sweet® SF) sufficient to make 180 mL. Store in amber glass bottles in the dark; label "shake well", "refrigerate", and "protect from light". Stable for 21 days refrigerated.Fish DN, Beall HD, Goodwin SD, et al, "Stability of Sumatriptan Succinate in Extemporaneously Prepared Oral Liquids," Am J Health Syst Pharm, 1997, 54(14):1619-22.9248606
Administer as soon as symptoms appear.
Powder: For intranasal administration with the Xsail device only. Remove the clear device cap from the reusable delivery device; remove one 11 mg disposable nosepiece from the foil pouch and click into the device body. Prior to administration, pierce the capsule inside the nosepiece by pressing and releasing the white piercing button one time on the device body. Insert the nosepiece into one nostril so there is a tight seal; rotate the device to place the mouthpiece in the mouth. Blowing forcefully through the mouthpiece for 2 to 3 seconds will deliver the powder into the nasal cavity; vibration may occur. Do not press white button while blowing into mouthpiece. Once administered into the first nostril, remove and discard nosepiece; repeat same process using a second 11 mg nosepiece into the other nostril to administer the remainder of the 22 mg dose.
Solution: Each nasal spray unit is preloaded with 1 dose; do not test the spray unit before use; remove unit from plastic pack when ready to use; while sitting down, gently blow nose to clear nasal passages; keep head upright and close one nostril gently with index finger; hold container with other hand, with thumb supporting bottom and index and middle fingers on either side of nozzle; insert nozzle into nostril about 1/2 inch; close mouth; take a breath through nose while releasing spray into nostril by pressing firmly on blue plunger; remove nozzle from nostril; keep head level for 10 to 20 seconds and gently breathe in through nose and out through mouth; do not breathe deeply.
SubQ: Not for IM or IV use. Needle penetrates 1/4 inch of skin; use in areas of the body with adequate skin and subcutaneous thickness (lateral thigh or upper arm). In patients receiving doses other than 4 or 6 mg, use the 6 mg single-dose vial instead of the autoinjector device.
Needleless administration (Sumavel DosePro): Administer to the abdomen (>2 inches from the navel) or thigh; not for IM or IV administration. Do not administer to other areas of the body (eg, arm). Device is for single use only, discard after use; do not use if the tip of the device is tilted or broken.
Alsuma: Store at 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F); do not refrigerate. Protect from light.
Imitrex injectable, tablet, intranasal: Store at 2°C to 30°C (36°F to 86°F). Protect from light.
Onzetra Xsail: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F); do not refrigerate or freeze. Use nosepiece immediately after removing from pouch (Onzetra Xsail).
Sumavel DosePro, Zembrace: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F); do not freeze (Sumavel DosePro). Protect from light.
Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Monitor therapy
Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Monitor therapy
Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators. Avoid combination
Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. Monitor therapy
Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives. Exceptions: Nicergoline. Avoid combination
Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Monitor therapy
Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Avoid combination
Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased. Monitor therapy
Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Monitor therapy
Monoamine Oxidase Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ. Avoid combination
Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Monitor therapy
Serotonin 5-HT1D Receptor Agonists: May enhance the adverse/toxic effect of SUMAtriptan. Avoid combination
Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur. Exceptions: Nicergoline; Tedizolid. Monitor therapy
TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. Monitor therapy
Central nervous system: Tingling sensation (14%), dizziness (≤12%), vertigo (≤12%), feeling hot (≤11%)
Local: Injection site reaction (59%), warm sensation at injection site (≤11%)
1% to 10%:
Cardiovascular: Flushing (7%), chest discomfort (5%), chest tightness (3%), local discomfort (jaw or throat: 2% to 3%), chest pressure (2%)
Central nervous system: Burning sensation (7%), feeling of heaviness (7%), sensation of pressure (7%), numbness (5%), paresthesia (5%), sensation of tightness (5%), drowsiness (≤3%), sedation (≤3%), headache (2%), strange feeling (2%), tight feeling in the head (2%)
Dermatologic: Diaphoresis (2%)
Gastrointestinal: Nausea and vomiting (4%)
Neuromuscular & skeletal: Neck pain (≤5%), neck stiffness (≤5%), weakness (5%), myalgia (2%)
Respiratory: Nasal discomfort (nasal cavity: ≤2%), sinus discomfort (≤2%), bronchospasm (1%)
Gastrointestinal: Dysgeusia (≤25%), unusual taste (≤25%), nausea (≤14%), vomiting (≤14%)
Respiratory: Nasal discomfort (≤11%)
1% to 10%:
Central nervous system: Localized numbness (≤5%), nasal cavity pain (≤5%), paresthesia (≤5%), dizziness (≤2%), vertigo (≤2%), localized burning (1%)
Local: Local irritation (≤5%)
Respiratory: Rhinorrhea (≤5%), sore nose (≤5%), nasal signs and symptoms (≤4%), sinus discomfort (≤4%), rhinitis (2%)
1% to 10%:
Cardiovascular: Hot and cold flashes (3%), chest pain (≤2%), chest pressure (≤2%), chest tightness (≤2%)
Central nervous system: Pain (≤8%), sensation of pressure (≤8%), paresthesia (3% to 5%), fatigue (≤3%), feeling of heaviness (≤3%), malaise (≤3%), sensation of tightness (≤3%), heaviness of chest (≤2%), vertigo (2%)
Gastrointestinal: Sore throat (≤3%)
Local: Local pain (2%)
Neuromuscular & skeletal: Jaw pain (≤3%), jaw pressure (≤3%), jaw tightness (≤3%), neck pain (≤3%)
Respiratory: Pharyngeal edema (≤3%)
Frequency not defined:
Cardiovascular: Ischemia, Raynaud phenomenon
Hematologic & oncologic: Splenic infarction
<1%, postmarketing, and/or case reports: Anaphylactoid reaction, anaphylaxis, angioedema, blindness, cerebral hemorrhage, cerebrovascular accident, dystonia, heaviness in neck (includes jaw or throat), hypersensitivity reaction, hypotension, myocardial infarction, neck pressure, neck tightness, seizure, subarachnoid hemorrhage, tremor, vision loss (partial)
Concerns related to adverse effects:
• Anaphylactic/anaphylactoid reactions: Anaphylactic, anaphylactoid, and hypersensitivity reactions (including angioedema) have been reported; may be life threatening or fatal.
• Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT1 agonist administration (some occurring within a few hours of administration). Discontinue sumatriptan if these events occur. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.
• Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke (may be fatal) have been reported with 5-HT1 agonist administration. Discontinue sumatriptan if a cerebrovascular event occurs.
• CNS depression: May cause CNS depression, such as dizziness, weakness, or drowsiness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).
• Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has been reported on rare occasions in patients with and without a history of hypertension. Use is contraindicated in patients with uncontrolled hypertension.
• Ocular effects: Transient and permanent blindness and significant partial vision loss have been reported (rare) with use of 5-HT1 agonist.
• Serotonin syndrome: Serotonin syndrome may occur with 5-HT1 agonists, particularly when used concomitantly with other serotonergic drugs; symptoms (eg, diarrhea, hyperreflexia, hyperthermia, incoordination, mental status changes, nausea, tachycardia, vomiting) typically occur minutes to hours after initiation/dose increase of a serotonergic drug. Discontinue use if serotonin syndrome is suspected.
• Vasospasm-related events: Peripheral vascular ischemia, GI vascular ischemia and infarction, splenic infarction, and Raynaud syndrome have been reported with 5-HT1 agonists.
• Coronary artery disease: Perform a cardiovascular evaluation in 5-HT1 agonists-naive patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male >40 years of age) prior to initiation of therapy. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is “satisfactory,” first dose should be given in the health care provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in these patients during intermittent long-term use.
• Hepatic impairment: Use oral formulations of sumatriptan with caution (and with dosage limitations) in patients with mild to moderate hepatic impairment where treatment is necessary and advisable. Presystemic clearance of orally administered sumatriptan is reduced in hepatic impairment, leading to increased plasma concentrations; dosage reduction of the oral product is recommended. Non-oral routes of administration (intranasal, subcutaneous) do not undergo similar hepatic first-pass metabolism and are not expected to result in significantly altered pharmacokinetics in patients with hepatic impairment. Use of the oral, intranasal, Alsuma, Imitrex, and Zembrace injectable is contraindicated in severe hepatic impairment; Sumavel is not recommended in severe hepatic impairment.
• Seizure disorders: Use with caution in patients with history of seizure disorder or in patients with a lowered seizure threshold; seizures have been reported after sumatriptan administration in patients with or without a history of seizures.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Elderly: Use with caution; perform a cardiovascular evaluation prior to initiation of therapy in elderly patients with cardiovascular risk factors (eg, diabetes, hypertension, smoking, obesity, strong family history of coronary artery disease) and periodically during intermittent long-term use.
Dosage form specific issues:
• Latex:The packaging (needle cover of prefilled syringe) may contain dry natural rubber, which is a derivative of latex.
• Appropriate use: Only indicated for the acute treatment of migraine or cluster headache (depending on product); not indicated for migraine or cluster headache prophylaxis, or for the treatment of hemiplegic or basilar migraine. Acute migraine agents (eg, 5-HT1 agonists, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse. If a patient does not respond to the first dose, the diagnosis of migraine or cluster headache should be reconsidered; rule out underlying neurologic disease in patients with atypical headache and in patients with no prior history of migraine or cluster headache.
Headache severity, blood pressure, signs/symptoms suggestive of angina; perform a cardiovascular evaluation prior to initiation of therapy in 5-HT1 agonist-naive patients who have multiple cardiovascular risk factors (eg, increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD); monitor ECG with first dose in patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation and consider periodic cardiovascular evaluation in such patients during intermittent long-term use.
Pregnancy Risk Factor
In a study using full-term, healthy human placentas, limited amounts of sumatriptan were found to cross the placenta (Schenker 1995).
Pregnancy outcome information for sumatriptan is available from a pregnancy registry sponsored by GlaxoSmithKline. As of September 2012, data were available for 617 pregnancies (626 infants/fetuses) exposed to sumatriptan (including 7 pregnancies also exposed to naratriptan). Following sumatriptan exposure, the risk of major birth defects following first trimester exposure was 4.2% and no consistent pattern of birth defects was observed. The pregnancy registry was closed to enrollment in January 2012 (Ephross 2014).
An analysis of data collected between 1995 and 2008 using the Swedish Medical Birth Register reported pregnancy outcomes following 5-HT1B/1D agonist exposure. An increased risk of major congenital malformations was not observed following sumatriptan exposure (2,229 exposed during the first trimester) (Källén 2011). An increased risk of major congenital malformations was also not observed using data collected from a Norwegian pregnancy registry study. This study included 415 women who used sumatriptan during the first trimester of pregnancy between 2004 and 2007 (Nezvalová-Henriksen 2013).
If treatment for cluster headaches is needed during pregnancy, sumatriptan may be used (Jürgens 2009). Other agents are preferred for the initial treatment of migraine in pregnancy (Da Silva 2012; MacGregor 2014; Williams 2012); however, sumatriptan may be considered if first-line agents fail (MacGregor 2014).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience flushing, feeling of warmth, loss of strength and energy, fatigue, bad taste, burning, rhinitis, pharyngitis, rhinorrhea, or injection site irritation. Have patient report immediately to prescriber signs of severe cerebrovascular disease (change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes), signs of a heart attack (angina; pain in arms, back, neck, jaw, or abdomen; shortness of breath; cold sweats; severe dizziness; passing out; or severe nausea or vomiting), abnormal heartbeat, tachycardia, seizures, blindness, severe headache, severe dizziness, passing out, vision changes, burning or numbness feeling, blue/gray skin discoloration, constipation, diarrhea, severe nausea, vomiting, severe abdominal pain, bloody diarrhea, weight loss, leg cramps, sensation of cold, feeling of heaviness in legs, burning or aching of feet, hearing impairment, or signs of serotonin syndrome (dizziness, severe headache, agitation, hallucinations, tachycardia, abnormal heartbeat, flushing, tremors, sweating a lot, change in balance, severe nausea, or severe diarrhea) (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
More about sumatriptan
- Sumatriptan Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Patient Tips
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- 388 Reviews
- Drug class: antimigraine agents
- Sumatriptan (AHFS Monograph)
- Sumatriptan Succinate (AHFS Monograph)
- Sumatriptan (FDA)
- Sumatriptan Injection (FDA)
- Sumatriptan Nasal Spray (FDA)